Eli Lilly's Triple-Action Obesity Drug Outperforms Tirzepatide

The experimental therapy pairs eloralintide—an amylin-targeting hormone—with a low dose of tirzepatide. By hitting three distinct biological pathways, the drug aims to suppress appetite more aggressively than existing GLP-1 treatments like Zepbound or Mounjaro. Over a 48-week period, participants on the highest dose lost an average of 54 pounds, compared to 34.4 pounds for the tirzepatide-only group. The combination also proved more effective at lowering A1C blood sugar levels, achieving a 2.9% reduction.

Despite these clinical gains, the regimen faces questions regarding patient tolerance. Discontinuation rates for the combo therapy reached as high as 27% due to gastrointestinal side effects, significantly higher than the 2.9% observed in the tirzepatide-only arm. Ken Custer, president of Lilly Cardiometabolic Health, dismissed these concerns as a typical hurdle in early-stage testing, noting that similar issues occurred during early trials of tirzepatide. Lilly intends to refine dosing schedules for Phase 3 trials set to begin later this year, with plans to move toward a single-injection co-formulation.